{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:16Z","timestamp":1791262816368,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T00:00:00Z","timestamp":1294790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p>Patients with follicular lymphoma (FL), where position 158 of Fc\u03b3R\u2010IIIa is heterozygous valine\/phenylalanine or homozygous phenylalanine (F\u2010carriers), have natural killer cells with lower binding affinity to IgG than valine homozygote patients. In addition, F\u2010carriers show less efficacy with rituximab treatment than patients homozygous for valine. LY2469298 is a humanized IgG1 monoclonal antibody targeting CD20, with human germline framework regions, and specific amino acid substitutions engineered into the Fc region to increase effector function in antibody\u2010dependent cell\u2010mediated cytotoxicity. This dose\u2010escalation, phase I study was conducted to assess the safety, pharmacokinetics and preliminary efficacy of LY2469298 in Japanese patients with previously treated, CD20\u2010positive FL who had not relapsed or progressed within 120\u2003days of prior rituximab. LY2469298 was administered by intravenous infusion at 100 or 375\u2003mg\/m<jats:sup>2<\/jats:sup> weekly for 4\u2003weeks. Ten patients were enrolled (median age, 60\u2003years); all had previously been treated with rituximab. Nine patients were F\u2010carriers while one was homozygous for valine at position 158 of Fc\u03b3RIIIa. No patients developed dose\u2010limiting toxicities, and the most frequent adverse events were lymphopenia, pyrexia, leukopenia, chills and neutropenia. Five (50%) of the ten patients responded to LY2469298 treatment (three complete responses, one unconfirmed complete response and one partial response). Serum LY2469298 was eliminated in a biphasic manner and the pharmacokinetic profiles were not different from those in a preceding study in the United States. In conclusion, LY2469298 was well tolerated and clinical activity was observed in FL patients pretreated with rituximab, mostly consisting of F\u2010carriers. Further investigation of FL is warranted. (<jats:italic>Cancer Sci<\/jats:italic> 2011; 102: 432\u2013438)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2010.01809.x","type":"journal-article","created":{"date-parts":[[2010,11,20]],"date-time":"2010-11-20T12:21:22Z","timestamp":1290255682000},"page":"432-438","source":"Crossref","is-referenced-by-count":25,"title":["Phase I study of LY2469298, an Fc\u2010engineered humanized anti\u2010CD20 antibody, in patients with relapsed or refractory follicular lymphoma"],"prefix":"10.1111","volume":"102","author":[{"given":"Kensei","family":"Tobinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Cronier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Wooldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Koshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903064824"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00173.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01703.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc\u03b3RIIIa\u2010158V\/F polymorphism influences the binding of IgG by natural killer cell Fc\u03b3RIIIa, independently of the Fc\u03b3RIIIa\u201048L\/R\/H phenotype","volume":"90","author":"Koene HR","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119616"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","unstructured":"ForeroA de VosS PohlmanBet\u00a0al.Preliminary results of a phase I study of AME\u2010133v an Fc\u2010engineered humanized monoclonal antibody in low\u2010affinity Fc\u03b3RIIIa patients with previously\u2010treated follicular lymphoma [abstract].American Association for Cancer Research 99thAnnual Meeting;April 12\u201016 2008; San Diego CA USA. Abstract LB\u201070.","DOI":"10.1158\/1538-7445.AM2008-LB-70"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single\u2010dose infusion of chimeric anti\u2010CD20 monoclonal antibody (IDEC\u2010C2B) in patients with recurrent B\u2010cell lymphoma","volume":"84","author":"Maloney DG","year":"1994","journal-title":"Blood"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265313133"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh176"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982806"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0463"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0697-4"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8957"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2010.01809.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2010.01809.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:05:26Z","timestamp":1697425526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2010.01809.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,12]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1349-7006.2010.01809.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01809.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,12]]}}}